

## 書籍

著者氏名	論文タイトル	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
峯岸克行	高IgE症候群	近藤直実/平家俊男	自己炎症性疾患・自然免疫不全症とその近縁疾患	診断と治療社	東京	2012	193-196
高田英俊	Mydosome異常症（IRAK4およびMyD88欠損症）	近藤直実/平家俊男	自己炎症性疾患・自然免疫不全症とその近縁疾患	診断と治療社	東京	2012	111-114
高田英俊	Mendel遺伝型マイコプラズマ肺炎易感染症（IL-12、IFN-g系の異常）	近藤直実/平家俊男	自己炎症性疾患・自然免疫不全症とその近縁疾患	診断と治療社	東京	2012	142-147
高田英俊	免疫不全症-自然免疫不全	原 寿郎	小児の発熱A to Z	診断と治療社	東京	2012	185-190
峯岸克行	原発性免疫不全症	矢崎義男	内科学 第10版	朝倉書店	東京	2013	1371-1378

雑誌 (英文)

発表者名	論文タイトル名	発表雑誌	巻号	ページ	出版年
Ma CS, Avery DT, Chan A, Batten M, Bustamante J, Boisson-Dupuis S, Arkwright PD, Kreins AY, Averbuch D, Engelhard D, Magdorf K, Kilic SS, Minegishi Y, Nonoyama S, French MA, Choo S, Smart JM, Peake J, Wong M, Gray P, Cook MC, Fulcher DA, Casanova JL, Deenick EK, Tangye SG.	Functional STAT3 deficiency compromises the generation of human T follicular helper cells.	Blood	119	3997-4008	2012
Ogawa H, Mukai K, Kawano Y, Minegishi Y, Karasuyama H.	Th2-inducing cytokines IL-4 and IL-33 synergistically elicit the expression of transmembrane TNF- $\alpha$ on macrophages through the autocrine action of IL-6	Biochem Biophys Res Commun.	420	114-118	2012
Minegishi Y, Saito M.	Cutaneous Manifestations of Hyper IgE Syndrome.	Allergol Int.	61	191-196	2012
Imagawa T, Nishikomori R, Takada H, Takeshita S, Patel N, Kim D, Lheritier K, Heike T, Hara T, Yokota S	Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results).	Clin Exp Rheumatol	in press		2013
Yokota S, Nishikomori R, Takada H, Kikuchi M, Nozawa T, Kanetaka T, Kizawa T, Miyamae T, Mori M, Heike T, Hara T, Imagawa T.	Guidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan.	Mod Rheumatol	in press		2013
Nozaki T, Takada H, Ishimura M, Ihara K, Imai K, Morio T, Kobayashi M, Nonoyama S, Hara T.	Endocrine complications in primary immunodeficiency diseases in Japan.	Clin Endocrinol	77	628-34	2012
Nanishi E, Ohga S, Doi T, Ishimura M, Ihara K, Takada H, Shima M, Hara T.	Complete immunotolerance induction after FEIBA prophylaxis in a haemophilia A patient with high-titre inhibitor.	Haemophilia	18	e75-7	2012
Shiraishi A, Ohga S, Doi T, Ishimura M, Takimoto T, Takada H, Miyamoto T, Abe Y, Hara T.	Treatment choice of immunotherapy or further chemotherapy for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.	Pediatr Blood Cancer	59	265-70	2012
Uchida Y, Matsubara K, Wada T, Oishi K, Morio T, Takada H, Iwata A, Yura K, Kamimura K, Nigami H, Fukaya T.	Recurrent bacterial meningitis by three different pathogens in an isolated asplenic child.	J Infect Chemother	18	576-80	2012
Wada T, Muraoka M, Toma T, Imai T, Shigemura T, Agematsu K, Haraguchi K, Moriuchi H, Oh-Ishi T, Kitoh T, Ohara O, Morio T, Yachie A.	Rapid Detection of Intracellular p47phox and p67phox by Flow Cytometry; Useful Screening Tests for Chronic Granulomatous Disease.	J Clin Immunol.	in press		
Shirasaki Y, Yamagishi M, Shimura N, Hijikata A, Ohara O.	Toward an understanding of immune cell sociology: real-time monitoring of cytokine secretion at the single-cell level.	IUBMB Life.	65(1)	28-34	2013
Kamae C, Nakagawa N, Sato H, Honma K, Mitsuiki N, Ohara O, Kanegane H, Pasic S, Pan-Hammarström Q, van Zelm MC, Morio T, Imai K, Nonoyama S.	Common variable immunodeficiency classification by quantifying T-cell receptor and immunoglobulin $\kappa$ -deleting recombination excision circles.	J Allergy Clin Immunol.	in press		
Kawasaki Y, Toyoda H, Otsuki S, Iwasa T, Iwamoto S, Azuma E, Itoh-Habe N, Wada H, Fujimura Y, Morio T, Imai K, Mitsuiki N, Ohara O, Komada Y.	A novel Wiskott-Aldrich syndrome protein mutation in an infant with thrombotic thrombocytopenic purpura.	Eur J Haematol.	90(2)	164-168	2013
Oshima K, Nagase T, Imai K, Nonoyama S, Obara M, Mizukami T, Nunoi H, Kanegane H, Kuribayashi F, Amemiya S, Ohara O.	A Dual Reporter Splicing Assay Using HaloTag-containing Proteins.	Curr Chem Genomics.	6	27-37	2012
Kaji T, Ishige A, Hikida M, Taka J, Hijikata A, Kubo M, Nagashima T, Takahashi Y, Kurosaki T, Okada M, Ohara O, Rajewsky K, Takemori T.	Distinct cellular pathways select germline-encoded and somatically mutated antibodies into immunological memory.	J Exp Med.	209(11)	2079-2097	2012
Hori T, Ohnishi H, Teramoto T, Tsubouchi K, Naiki T, Hirose Y, Ohara O, Seishima M, Kaneko H, Fukao T, Kondo N.	Autosomal-Dominant Chronic Mucocutaneous Candidiasis with STAT1-Mutation can be Complicated with Chronic Active Hepatitis and Hypothyroidism.	J Clin Immunol.	32(6)	1213-1220	2012

Takezaki S, Yamada M, Kato M, Park MJ, Maruyama K, Yamazaki Y, Chida N, Ohara O, Kobayashi I, Ariga T.	Chronic mucocutaneous candidiasis caused by a gain-of-function mutation in the STAT1 DNA-binding domain.	J Immunol.	189(3)	1521-1526	2012
Suri D, Singh S, Rawat A, Gupta A, Kamae C, Honma K, Nakagawa N, Imai K, Nonoyama S, Oshima K, Mitsuiki N, Ohara O, Bilhou-Nabera C, Proust A, Ahluwalia J, Dogra S, Saikia B, Minz RW, Sehgal S.	Clinical profile and genetic basis of Wiskott-Aldrich syndrome at Chandigarh, North India.	Asian Pac J Allergy Immunol.	30(1)	71-78	2012
Mohammadzadeh I, Yeganeh M, Aghamohammadi A, Parvaneh N, Behniafard N, Abolhassani H, Tabassomi F, Hemmat M, Kanegane H, Miyawaki T, Ohara O, Rezaei N.	Severe primary antibody deficiency due to a novel mutation of mu heavy chain.	J Investig Allergol Clin Immunol.	22(1)	78-79	2012
Nakaoka H, Kanegane H, Taneichi H, Miya K, Yang X, Nomura K, Takezaki S, Yamada M, Ohara O, Kamae C, Imai K, Nonoyama S, Wada T, Yachie A, Hershfield MS, Ariga T, Miyawaki T.	Delayed onset adenosine deaminase deficiency associated with acute disseminated encephalomyelitis.	Int J Hematol.	95(6)	692-696	2012
Izawa K, Hijikata A, Tanaka N, Kawai T, Saito MK, Goldbach-Mansky R, Aksentijevich I, Yasumi T, Nakahata T, Heike T, Nishikomori R, Ohara O.	Detection of base substitution-type somatic mosaicism of the NLRP3 gene with >99.9% statistical confidence by massively parallel sequencing.	DNA Res.	19(2)	143-152	2012
Mizuno T, Sakai H, Nishikomori R, Oshima K, Ohara O, Hata I, Shigematsu Y, Ishige T, Tamura K, Arakawa H.	Novel mutations of MYK gene in Japanese family members affected with hyperimmunoglobulinemia D and periodic fever syndrome.	Rheumatol Int.	32(12)	3761-3764	2012
Kinose D, Ogawa E, Hirota T, Ito I, Kudo M, Haruna A, Marumo S, Hoshino Y, Muro S, Hirai T, Sakai H, Date H, Tamari M, Mishima M.	A NOD2 gene polymorphism is associated with the prevalence and severity of chronic obstructive pulmonary disease in a Japanese population.	Respirology	17	164-171	2012
Chang WC, Lee CH, Hirota T, Wang LF, Doi S, Miyatake A, Enomoto T, Tomita K, Sakashita M, Yamada T, Fujieda S, Ebe K, Saeki H, Takeuchi S, Furue M, Chen WC, Chiu YC, Chang WP, Hong CH, His E, Hank Joo SH, Yu HS, Nakamura Y, Tamari M.	ORAI1 genetic polymorphisms associated with the susceptibility of atopic dermatitis in Japanese and Taiwanese populations.	PLoS One	7	e29387	2012
Himes BE, Jiang X, Hu R, Wu AC, Lasky-Su JA, Klanderma BJ, Ziniti J, Senter-Sylvia J, Lima JJ, Irvin CG, Peters SP, Meyers DA, Bleecker ER, Kubo M, Tamari M, Nakamura Y, Szeffler SJ, Lemanske RF Jr, Zeiger RS, Strunk RC, Martinez FD, Hanrahan JP, Koppelman GH, Postma DS, Nieuwenhuis MA, Vonk JM, Panettieri RA Jr, Markezich A, Israel E, Carey VJ, Tantisira KG, Litonjua AA, Lu Q, Weiss ST.	Genome-wide association analysis in asthma subjects identifies SPAT2L as a novel bronchodilator response gene.	PLoS Genet	8	e1002824	2012
Yamaide F, Undarmaa S, Mashimo Y, Shimojo N, Arima T, Morita Y, Hirota T, Fujita K, Miyatake A, Doi S, Sato K, Suzuki S, Nishimuta T, Watanabe H, Hoshioka A, Tomiita M, Yamaide A, Watanabe M, Okamoto Y, Kohno Y, Tamari M, Hata A, Suzuki Y.	Association Study of Matrix Metalloproteinase-12 Gene Polymorphisms and Asthma in a Japanese Population.	Int Arch Allergy Immunol	160	287-296	2012
Kumasaka N, Aoki M, Okada Y, Takahashi A, Ozaki K, Mushiroda T, Hirota T, Tamari M, Tanaka T, Nakamura Y, Kamatani N, Kubo M.	Haplotypes with Copy Number and Single Nucleotide Polymorphisms in CYP2A6 Locus Are Associated with Smoking Quantity in a Japanese Population.	PLoS One	7	e44507	2012
Hirota T, Takahashi A, Kubo M, Tsumoda T, Tomita K, Sakashita M, Yamada T, Fujieda S, Tanaka S, Doi S, Miyatake A, Enomoto T, Nishiyama C, Nakano N, Maeda K, Okumura K, Ogawa H, Ikeda S, Noguchi E, Sakamoto T, Hizawa N, Ebe K, Saeki H, Sasaki T, Ebihara T, Amagai M, Takeuchi S, Furue M, Nakamura Y, Tamari M.	Genome-wide association study identifies eight new susceptibility loci for atopic dermatitis in the Japanese population.	Nat Genet	44	1222-1226	2012
Tomita K, Sakashita M, Hirota T, Tanaka S, Masuyama K, Yamada T, Fujieda S, Miyatake A, Hizawa N, Kubo M, Nakamura Y, Tamari M.	Variants in the 17q21 asthma susceptibility locus are associated with allergic rhinitis in the Japanese population.	Allergy	68	92-100	2013
Iijima H, Kaneko Y, Yamada H, Yatagai Y, Masuko H, Sakamoto T, Naito T, Hirota T, Tamari M, Konno S, Nishimura M, Noguchi E, Hizawa N.	A distinct sensitization pattern associated with asthma and the thymic stromal lymphopoietin genotype.	Allergol Int		in press	2013
Egawa M, Mukai K, Yoshikawa S, Iki M, Kawano Y, Minegishi Y, Karasuyama H.	Inflammatory monocytes recruited to allergen-exposed skin acquire an anti-inflammatory property via basophil-derived IL-4.	Immunity	38	570-580	2013
Obata-Ninomiya K, Ishiwata K, Tsutsui H, Nei Y, Yoshikawa S, Kawano Y, Minegishi Y, Ohta N, Watanabe N, Kanuka H, Karasuyama H.	The skin is an important bulwark of acquired immunity against intestinal helminthes.	J Exp Med	210	2583-2595	2013
Kumaki S, Sasahara Y, Kamachi Y, Muramatsu H, Morio T, Goi K, Sugita K, Urabe T, Takada H, Kojima S, Tsuchiya S, Hara T.	B cell function after unrelated umbilical cord blood transplantation using minimal-intensity conditioning regimen in patients with X-SCID.	Int J Hematol.	98	355-60	2013
Doi T, Ohga S, Ishimura M, Takada H, Ishii K, Ihara K, Nagai H, Hara T.	Long-term liposteroid therapy for idiopathic pulmonary hemosiderosis.	Eur J Pediatr.	172	1475-81	2013

Ishimura M, Yamamoto H, Mizuno Y, Takada H, Goto M, Doi T, Hoshina T, Ohga S, Ohshima K, Hara T.	A non-invasive diagnosis of histiocytic necrotizing lymphadenitis by means of gene expression profile analysis of peripheral blood mononuclear cells.	J Clin Immunol	33	1018-26	2013
Imagawa T, Nishikomori R, Takada H, Takeshita S, Patel N, Kim D, Lheritier K, Heike T, Hara T, Yokota S	Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results).	Clin Exp Rheumatol.	31	302-9	2013
Yokota S, Nishikomori R, Takada H, Kikuchi M, Nozawa T, Kanetaka T, Kizawa T, Miyamae T, Mori M, Heike T, Hara T, Imagawa T.	Guidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan.	Mod Rheumatol.	23	425-9	2013
Muñoz-Ruiz M, Pérez-Flores V, Garcillán B, Guardo AC, Mazariegos MS, Takada H, Allende LM, Kilic SS, Sanal O, Roifman CM, López-Granados E, Recio MJ, Martínez-Naves E, Fernández-Malavé E, Regueiro JR.	Human CD3 $\gamma$ , but not CD3 $\delta$ , haploinsufficiency differentially impairs $\gamma\delta$ versus $\alpha\beta$ surface TCR expression.	BMC Immunol.	14	3	2013
Ninomiya T, Takada H, Nagatomo Y, Nanishi E, Nagata H, Yamamura K, Doi T, Ikeda I, Hara T.	Development of Kawasaki disease in a patient with PFAPA.	Pediatr Int.	55	801-2	2013
Higuchi Y, Shimizu J, Hatanaka M, Kitano E, Kitamura H, Takada H, Ishimura M, Hara T, Ohara O, Asagoe K, Kubo T.	The identification of a novel splicing mutation in C1qB in a Japanese family with C1q deficiency: a case report.	Pediatr Rheumatol Online J.	11	41	2013
Takada H	Primary immunodeficiency in Japan; epidemiology, diagnosis, and pathogenesis.	Pediatr Int.	55	671-4	2013
Saito Y, Kagami SI, Sanayama Y, Ikeda K, Suto A, Kashiwakuma D, Furuta S, Iwamoto I, Nonaka K, Ohara O, Nakajima H.	AT-rich interactive domain-containing protein 5a functions as a negative regulator of ROR $\gamma$ t-induced Th17 cell differentiation.	Arthritis Rheum.	in press		2013
Wada T, Sakakibara Y, Nishimura R, Toma T, Ueno Y, Horita S, Tanaka T, Nishi M, Kato K, Yasumi T, Ohara O, Yachie A.	Down-regulation of CD5 expression on activated CD8(+) T cells in familial hemophagocytic lymphohistiocytosis with perforin gene mutations.	Hum Immunol.	74;12	1579-1585	2013
Lee YW, Yang EA, Kang HJ, Yang X, Mitsuiki N, Ohara O, Miyawaki T, Kanegane H, Lee JH.	Novel mutation of IL2RG gene in a Korean boy with X-linked severe combined immunodeficiency.	J Invest Allergol Clin Immunol.	23;1	65-67	2013
Suzuki J, Kuwahara M, Tofukuji S, Imamura M, Kato F, Nakayama T, Ohara O, Yamashita M.	A novel small compound SH-2251 suppresses Th2 cell-dependent airway inflammation through selective modulation of chromatin status at the Il5 gene locus.	PLoS One.	16;8	e61785	2013
Wada T, Muraoka M, Toma T, Imai T, Shigemura T, Agematsu K, Haraguchi K, Moriuchi H, Oh-Ishi T, Kitoh T, Ohara O, Morio T, Yachie A.	Rapid detection of intracellular p47p <sub>hox</sub> and p67p <sub>hox</sub> by flow cytometry; useful screening tests for chronic granulomatous disease.	J Clin Immunol.	33;4	857-864	2013
Kamae C, Nakagawa N, Sato H, Honma K, Mitsuiki N, Ohara O, Kanegane H, Pasie S, Pan-Hammarström Q, van Zelm MC, Morio T, Imai K, Nonoyama S.	Common variable immunodeficiency classification by quantifying T-cell receptor and immunoglobulin $\kappa$ -deleting recombination excision circles.	J Allergy Clin Immunol.	131;5	1437-1440	2013
Tomita K, Sakashita M, Hirota T, Tanaka S, Masuyama K, Yamada T, Fujieda S, Miyatake A, Hizawa N, Kubo M, Nakamura Y, Tamari M	Variants in the 17q21 asthma susceptibility locus are associated with allergic rhinitis in the Japanese population.	Allergy	68	92-100	2013
Iijima H, Kaneko Y, Yamada H, Yatagai Y, Masuko H, Sakamoto T, Naito T, Hirota T, Tamari M, Konno S, Nishimura M, Noguchi E, Hizawa N	A distinct sensitization pattern associated with asthma and the thymic stromal lymphopoietin (TSLP) genotype.	Allergol Int	62	123-130	2013
Himes BE, Sheppard K, Berndt A, Leme AS, Myers RA, Gignoux CR, Levin AM, Gauderman WJ, Yang JJ, Mathias RA, Romieu I, Torgerson DG, Roth LA, Huntsman S, Eng C, Klanderma B, Ziniti J, Senter-Sylvia J, Szeffler SJ, Lemanske RF Jr, Zeiger RS, Strunk RC, Martinez FD, Boushey H, Chinchilli VM, Israel E, Mauger D, Koppelman GH, Postma DS, Nieuwenhuis MA, Vonk JM, Lima JJ, Irvin CG, Peters SP, Kubo M, Tamari M, Nakamura Y, Litonjua AA, Tantisira KG, Raby BA, Bleeker ER, Meyers DA, London SJ, Barnes KC, Gilliland FD, Williams LK, Burchard EG, Nicolae DL, Ober C, DeMeo DL, Silverman EK, Paigen B, Churchill G, Shapiro SD, Weiss ST	Integration of mouse and human genome-wide association data identifies KCNP4 as an asthma gene.	PLoS One	8	e56179	2013
Saeki H, Hirota T, Nakagawa H, Tsunemi Y, Kato T, Shibata S, Sugaya M, Sato S, Doi S, Miyatake A, Ebe K, Noguchi E, Ebihara T, Amagai M, Esaki H, Takeuchi S, Furue M, Nakamura Y, Tamari M	Genetic polymorphisms in the IL22 gene are associated with psoriasis vulgaris in a Japanese population.	J Dermatol Sci	71	148-150	2013

Ellinghaus D, Baurecht H, Esparza-Gordillo J, Rodriguez E, Matanovic A, Marenholz I, Hübner N, Schaarschmidt H, Novak N, Michel S, Maintz L, Werfel T, Meyer-Hoffert U, Hotze M, Prokisch H, Heim K, Herder C, Hirota T, Tamari M, Kubo M, Takahashi A, Nakamura Y, Tsoi LC, Stuart P, Elder JT, Sun L, Zuo X, Yang S, Zhang X, Hoffmann P, Nöthen MM, Fölster-Holst R, Winkelmann J, Illig T, Boehm BO, Duerr RH, Büning C, Brand S, Glas J, McAleer MA, Fahy CM, Kabesch M, Brown S, McLean WH, Irvine AD, Schreiber S, Lee YA, Franke A, Weidinger S	High-density genotyping study identifies four new susceptibility loci for atopic dermatitis.	Nat Genet	45	808-812	2013
Kanemitsu Y, Matsumoto H, Izuhara K, Tohda Y, Kita H, Horiguchi T, Kuwabara K, Tomii K, Otsuka K, Fujimura M, Ohkura N, Tomita K, Yokoyama A, Ohnishi H, Nakano Y, Oguma T, Hozawa S, Nagasaki T, Ito I, Oguma T, Inoue H, Tajiri T, Iwata T, Izuhara Y, Ono J, Ohta S, Tamari M, Hirota T, Yokoyama T, Niimi A, Mishima M	Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids.	J Allergy Clin Immunol	132	305-312	2013
Tanaka S, Hirota T, Kamijo A, Ishii H, Hatsushika K, Fujieda S, Ishitoya J, Masuyama K, Tamari M	Lung Functions of Japanese Patients with Chronic Rhinosinusitis Who Underwent Endoscopic Sinus Surgery.	Allergol Int		in press	2013
Wu AC, Himes BE, Lasky-Su J, Litonjua A, Peters SP, Lima J, Kubo M, Tamari M, Nakamura Y, Qiu W, Weiss ST, Tantisira K	Inhaled corticosteroid treatment modulates ZNF432 gene variant's effect on bronchodilator response in asthmatics.	J Allergy Clin Immunol	13	in press	2013
Yatagai Y, Sakamoto T, Masuko H, Kaneko Y, Yamada H, Iijima H, Naito T, Noguchi E, Hirota T, Tamari M, Imoto Y, Tokunaga T, Fujieda S, Konno S, Nishimura M, Hizawa N	Genome-Wide Association Study for Levels of Total Serum IgE Identifies HLA-C in a Japanese Population.	PLoS One	8	e80941	2013
Hayashi M, Hirota T, Saeki H, Nakagawa H, Ishiiji Y, Matsuzaki H, Tsunemi Y, Kato T, Shibata S, Sugaya M, Sato S, Tada Y, Doi S, Miyatake A, Ebe K, Noguchi E, Ebihara T, Amagai M, Esaki H, Takeuchi S, Furue M, Tamari M	Genetic polymorphism in the TRAF3IP2 gene is associated with psoriasis vulgaris in a Japanese population.	J Dermatol Sci	13	in press	2013
Tamari M, Tanaka S, Hirota T	Genome-wide association studies of allergic diseases.	Allergol Int	62	21-28	2013
Tamari M, Hirota T	Genome-wide association studies of atopic dermatitis.	J Dermatology		in press	2013

## 雑誌 (和文)

発表者名	論文タイトル名	発表雑誌	巻号	ページ	出版年
峯岸克行	高IgE症候群	知っておきたい内科症候群	109	1495-1496	2012
峯岸克行	高IgM症候群	知っておきたい内科症候群	109	1497-1498	2012
峯岸克行	高IgE症候群と感染症	化学療法の領域	27	80-84	2012
峯岸克行	高IgE症候群の原因遺伝子解析の現況と臨床応用の可能性	日本医事新報	4610	57-58	2012
峯岸克行	高IgE症候群により発症するアトピー性皮膚炎	臨床免疫・アレルギー科	58	667-670	2012
高田英俊、大賀正一、原 寿郎	自己炎症症候群。特集 知っておきたい最新の免疫不全症候群分類-診断から治療まで-	小児科診療	in press		2013
高田英俊	新生児の自然免疫能	臨床免疫・アレルギー科	57	582-6	2012
高田英俊	X連鎖リンパ増殖症候群	小児内科	44	238-9	2012
横田俊平、西小森隆太、高田英俊、菊池雅子、野澤 智、金高太一、木澤敏毅、宮前多佳子、森雅亮、平家俊男、原 寿郎、今川	クリオピリン関連周期性発熱症候群に対する生物学的製剤治療の手引き (2012) カナキヌマブ	日本小児科学会雑誌	116	1337-41	2012
瀧本智仁、古賀友紀、高田英俊	HLA検査 小児検査法便覧 血液 移植関連検査	小児科診療	in press		2013
田中翔太、富田かおり、広田朝光、玉利真由美	特集、呼吸器病学 TOPICS 2012 2. 呼吸器疾患と自然免疫。	アレルギー・免疫・炎症	16	34-36	2012
広田朝光、富田かおり、田中翔太、玉利真由美	遺伝・ゲノム学 日本人成人気管支喘息のゲノムワイド関連解析	医学のあゆみ	240	535-537	2012
玉利真由美、広田朝光	遺伝子解析から考えるアレルギー疾患の治療戦略-アレルギー疾患は克服できるか?	日本医事新報	4592	81-85	2012
広田朝光、田中翔太、玉利真由美	解説(基礎) GWASによる疾患遺伝子の解明	呼吸	31	605-611	2012
玉利真由美、田中翔太、広田朝光	特集 多遺伝子疾患 呼吸器疾患のゲノムワイド関連解析	BioClinica	27	1044-1048	2012
峯岸克行	STAT3の異常によるアトピー性皮膚炎の発症機序	臨床・免疫アレルギー科	59	160-164	2013
峯岸克行	高IgE症候群の最近の話題	Medical Science Digest	39	7-8	2013
峯岸克行	抗体産生不全症-B細胞不全症	小児科診療	76	419-423	2013
峯岸克行	Jak-Statシグナルとアレルギー制御	実験医学増刊号	31	113-117	2013
峯岸克行	高IgE症候群に見られる易感染性	化学療法の領域	29	2429-2434	2013
峯岸克行	高IgE症候群	小児内科	45	1146-1147	2013
河合朋樹、高田英俊	病態 自然免疫異常 - MyD88/IRAK4欠損症、免疫不全を伴う無汗性外胚葉形成異常、特集 知っておきたい最新の免疫不全症候群分類-診断から治療まで-	小児科診療	76	439-45	2013
高田英俊	病態 自己炎症性疾患。特集 知っておきたい最新の免疫不全症候群分類-診断から治療まで-	小児科診療	76	447-52	2013
高田英俊	特定の病原体に易感染性を示す原発性免疫不全症候群 原発性免疫不全症の診断と治療 Update	小児科臨床	66	1033-9	2013
瀧本智仁、古賀友紀、高田英俊	移植関連検査 理解して出そう小児の検査	小児科診療 2013年増刊号	76 Suppl	152-156	2013
玉利真由美、田中翔太、角大治朗、広田朝光	ゲノムワイド関連解析と呼吸器多因子疾患。	呼吸	32 (3)	274-279	2013
広田朝光、玉利真由美	疾患概念と病因論 ゲノム解析。COPD (慢性閉塞性肺疾患) 病態解明から治療まで	最新医学		1072-1078	2013
広田朝光、玉利真由美	日本人の遺伝的背景とアレルギー。	実験医学増刊号	31	2872-2878	2013
広田朝光、玉利真由美	ゲノム解析と気管支喘息。	呼吸と循環	61	906-913	2013
玉利真由美、広田朝光	ゲノムワイド関連解析と呼吸器疾患。第1章 病態生理に関する最新の基礎的研究	別冊 医学のあゆみ 呼吸器疾患	Ver. 6 state of arts	61-63	2013
玉利真由美、広田朝光	遺伝的アプローチから見た小児気管支喘息。	日本小児アレルギー学会誌		539-547	2013

### Ⅲ 代表的な研究成果の刊行物

# blood

2012 119: 3997-4008  
Prepublished online March 8, 2012;  
doi:10.1182/blood-2011-11-392985

## Functional STAT3 deficiency compromises the generation of human T follicular helper cells

Cindy S. Ma, Danielle T. Avery, Anna Chan, Marcel Batten, Jacinta Bustamante, Stephanie Boisson-Dupuis, Peter D. Arkwright, Alexandra Y. Kreins, Diana Averbuch, Dan Engelhard, Klaus Magdorf, Sara S. Kilic, Yoshiyuki Minegishi, Shigeaki Nonoyama, Martyn A. French, Sharon Choo, Joanne M. Smart, Jane Peake, Melanie Wong, Paul Gray, Matthew C. Cook, David A. Fulcher, Jean-Laurent Casanova, Elissa K. Deenick and Stuart G. Tangye

---

Updated information and services can be found at:  
<http://bloodjournal.hematologylibrary.org/content/119/17/3997.full.html>

Articles on similar topics can be found in the following Blood collections  
Immunobiology (4974 articles)

---

Information about reproducing this article in parts or in its entirety may be found online at:  
[http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub\\_requests](http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests)

Information about ordering reprints may be found online at:  
<http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints>

Information about subscriptions and ASH membership may be found online at:  
<http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml>

Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036.  
Copyright 2011 by The American Society of Hematology; all rights reserved.



## Functional STAT3 deficiency compromises the generation of human T follicular helper cells

Cindy S. Ma,<sup>1,2</sup> Danielle T. Avery,<sup>1</sup> Anna Chan,<sup>1</sup> Marcel Batten,<sup>1,2</sup> Jacinta Bustamante,<sup>3,4</sup> Stephanie Boisson-Dupuis,<sup>3,5</sup> Peter D. Arkwright,<sup>6</sup> Alexandra Y. Kreins,<sup>5</sup> Diana Averbuch,<sup>7</sup> Dan Engelhard,<sup>7</sup> Klaus Magdorf,<sup>8</sup> Sara S. Kilic,<sup>9</sup> Yoshiyuki Minegishi,<sup>10</sup> Shigeaki Nonoyama,<sup>11</sup> Martyn A. French,<sup>12,13</sup> Sharon Choo,<sup>14</sup> Joanne M. Smart,<sup>14</sup> Jane Peake,<sup>15</sup> Melanie Wong,<sup>16</sup> Paul Gray,<sup>17</sup> Matthew C. Cook,<sup>18-20</sup> David A. Fulcher,<sup>21</sup> Jean-Laurent Casanova,<sup>3,5</sup> Elissa K. Deenick,<sup>1,2</sup> and Stuart G. Tangye<sup>1,2</sup>

<sup>1</sup>Immunology Research Program, Garvan Institute of Medical Research, Darlinghurst, Australia; <sup>2</sup>St Vincent's Clinical School, University of New South Wales, Sydney, Australia; <sup>3</sup>Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Inserm U550, Necker Medical School, Université Paris Descartes, Paris, France; <sup>4</sup>Center for the Study of Primary Immunodeficiencies, Assistance Publique des Hôpitaux de Paris (AP-HP), Necker Hospital, Paris, France; <sup>5</sup>Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY; <sup>6</sup>University of Manchester, Royal Manchester Children's Hospital, Manchester, United Kingdom; <sup>7</sup>Department of Pediatrics and Pediatric Infectious Diseases, Hadassah-Hebrew University Medical Centre, Ein-Kerem, Jerusalem, Israel; <sup>8</sup>Department of Pediatric Pneumology and Immunology, Charité, Humboldt University of Berlin, Berlin, Germany; <sup>9</sup>Department of Pediatrics, Uludag University School of Medicine, Bursa, Turkey; <sup>10</sup>Department of Immune Regulation, Tokyo Medical and Dental University Graduate School, Tokyo, Japan; <sup>11</sup>Department of Pediatrics, National Defense Medical College, Saitama, Japan; <sup>12</sup>Department of Clinical Immunology, Royal Perth Hospital, Perth, Australia; <sup>13</sup>School of Pathology and Laboratory Medicine, University of Western Australia, Perth, Australia; <sup>14</sup>Department of Allergy and Immunology, Royal Children's Hospital, Melbourne, Australia; <sup>15</sup>Department of Paediatrics and Child Health, Royal Children's Hospital Brisbane, Brisbane, Australia; <sup>16</sup>Department of Immunology, Children's Hospital at Westmead, Australia; <sup>17</sup>University of New South Wales School of Women's and Children's Health, NSW, Australia; <sup>18</sup>Australian National University Medical School, Australian National University, Canberra, Australia; <sup>19</sup>John Curtin School of Medical Research, Australian National University, Canberra, Australia; <sup>20</sup>Department of Immunology, The Canberra Hospital, Canberra, Australia; and <sup>21</sup>Department of Immunology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Australia

**T follicular helper (Tfh) cells are critical for providing the necessary signals to induce differentiation of B cells into memory and Ab-secreting cells. Accordingly, it is important to identify the molecular requirements for Tfh cell development and function. We previously found that IL-12 mediates the differentiation of human CD4<sup>+</sup> T cells to the Tfh lineage, because IL-12 induces naive human CD4<sup>+</sup> T cells to acquire expression of IL-21, BCL6, ICOS, and CXCR5, which**

**typify Tfh cells. We have now examined CD4<sup>+</sup> T cells from patients deficient in IL-12Rβ1, TYK2, STAT1, and STAT3 to further explore the pathways involved in human Tfh cell differentiation. Although STAT1 was dispensable, mutations in *IL12RB1*, *TYK2*, or *STAT3* compromised IL-12-induced expression of IL-21 by human CD4<sup>+</sup> T cells. Defective expression of IL-21 by STAT3-deficient CD4<sup>+</sup> T cells resulted in diminished B-cell helper activity in vitro. Importantly, muta-**

**tions in *STAT3*, but not *IL12RB1* or *TYK2*, also reduced Tfh cell generation in vivo, evidenced by decreased circulating CD4<sup>+</sup>CXCR5<sup>+</sup> T cells. These results highlight the nonredundant role of STAT3 in human Tfh cell differentiation and suggest that defective Tfh cell development and/or function contributes to the humoral defects observed in STAT3-deficient patients. (*Blood*. 2012;119(17):3997-4008)**

### Introduction

The generation of robust Ab responses is crucial for the correct functioning of the immune system. The importance of this is apparent in diseases that result from dysregulated humoral immune responses. For example, immunodeficient states and autoimmune disorders can develop as a consequence of impaired or exaggerated Ab responses, respectively. Thus, it is imperative to identify factors that control Ab responses. Early studies found that T cells play an important role in initiating Ab responses (reviewed in Tangye et al<sup>1</sup>). This was mediated by instructive signals in the form of cell-cell contacts and secretion of soluble mediators such as cytokines. More recently, a subset of CD4<sup>+</sup> T cells with specialized B-cell helper capabilities was identified that is now referred to as T follicular helper (Tfh) cells.<sup>2,3</sup> Tfh cells are identified by several characteristics that also serve functional roles. Thus, Tfh cells express the chemokine receptor CXCR5,<sup>2,3</sup> which facilitates their

positioning to B-cell follicles in secondary lymphoid tissues, and the transcription factor Bcl-6,<sup>4</sup> which is required for the commitment of naive CD4<sup>+</sup> T cells to the Tfh lineage.<sup>5-7</sup> Tfh cells also express the costimulatory molecules CD40L, ICOS, OX40, and members of the SLAM family, as well as the cytokine IL-21,<sup>2-4,8-12</sup> all of which play important roles in the induction of T cell-dependent (TD) B-cell activation and differentiation.

Because of the importance of Tfh cells in regulating Ab responses, much work has been performed to determine the requirements for their differentiation from naive CD4<sup>+</sup> T cells. It was initially found that IL-21 was required for the development of murine Tfh cells.<sup>13,14</sup> This was later expanded to include IL-6 and IL-27.<sup>15-17</sup> However, conflicting findings have been made about the relative importance of IL-6 and IL-21 to murine Tfh cell formation<sup>18,19</sup>; this may reflect redundancy because these cytokines, as

Submitted November 22, 2011; accepted February 28, 2012. Prepublished online as *Blood* First Edition paper, March 8, 2012; DOI 10.1182/blood-2011-11-392985.

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2012 by The American Society of Hematology

**Table 1. Primary immunodeficient patients**

Disease	Patient ID	Mutation/genotype	
MSMD (IL-12Rβ1 deficiency)	IL12RB1#1	1745_1746insCA+1483 + 182-1619-1073del	
	IL12RB1#2	628_644dup	
	IL12RB1#3	R173P	
	IL12RB1#4	1791 + 2T > G	
	IL12RB1#5	C198R	
	IL12RB1#6	1623_1624delinsTT	
MSMD + viral infection (STAT1 deficiency)	STAT1#1	1928insA (homozygous)	
	STAT1#2	P696S (homozygous)	
	STAT1#3	P696S (homozygous)	
MSMD only (STAT1 deficiency)	STAT1#4	Q463H/WT	
	STAT1#5	L706S/WT	
	STAT1#6	L706S/WT	
AD-CMC	STAT1gof#1	A267V	
	STAT1gof#2	A267V	
	STAT1gof#3	A267V	
AD-HIES	STAT3#1	R382Q	
	STAT3#2	V637M	
	STAT3#3	R382Q	
	STAT3#4	H437P	
	STAT3#5	Q644P	
	STAT3#6	S465F	
	STAT3#7	Y657N	
	STAT3#8	R382W	
	STAT3#9	L706M	
	STAT3#10	L706M	
	STAT3#13	V463del	
	STAT3#14	V463del	
	STAT3#15	R593P	
	STAT3#16	V463del	
	AR-HIES (incl infection with mycobacteria, viruses and fungi)	TYK2#1	550_553GCTTdel (homozygous)
	MSMD + viral infection	TYK2#2	2292-2301del

MSMD indicates Mendelian susceptibility to mycobacterial disease; WT, wild type; AD-CMC, autosomal dominant chronic mucocutaneous candidiasis; AD-HIES, autosomal dominant hyper-IgE syndrome; AR-HIES, autosomal recessive hyper-IgE syndrome; and gof, gain-of-function

well as IL-27, can operate through STAT3.<sup>20,21</sup> We and others previously showed that IL-12 is the key cytokine implicated in the differentiation of human Tfh cells in vitro.<sup>11,22</sup> IL-6, IL-21, IL-23, and IL-27 also induce human Tfh-like cells in vitro, albeit to a much lesser extent than IL-12.<sup>11,17,22</sup> We have now extended these observations by investigating the molecular requirements for the differentiation of naive human CD4<sup>+</sup> T cells into Tfh cells. This was achieved by studying patients with primary immunodeficiencies resulting from mutations in *IL12RB1*, *STAT1*, *STAT3*, and *TYK2*. IL-12-mediated induction of human Tfh-like cells was abolished in the absence of IL-12Rβ1 or TYK2, and significantly reduced in CD4<sup>+</sup> T cells deficient in STAT3 function. In contrast to the effects of IL-12, induction of Tfh cells by IL-6, IL-21, IL-23, and IL-27 was completely dependent on STAT3. These studies indicate that multiple cytokine pathways are involved in the differentiation of human Tfh cells, and IL-12 most efficiently induces human Tfh cells predominantly in a STAT3-dependent manner. This defect in generating Tfh cells from STAT3 mutant (*STAT3*<sub>MUT</sub>) CD4<sup>+</sup> T cells would contribute to impaired TD humoral immune responses observed in patients with *STAT3* mutations. In contrast, the ability of non-IL-12 cytokines to induce Tfh cell function is sufficient to elicit intact Ab responses in persons with impaired IL-12R signaling.

## Methods

### Human patient samples

Patients with mutations in *IL12RB1*, *STAT1*, *TYK2*, and *STAT3* have been previously described (Table 1<sup>23-28</sup>). PBMCs were isolated from these patients and healthy donors (Australian Red Cross). Tonsils were obtained from St Vincent's Hospital, Sydney. All studies were approved by Institutional Human Research Ethics Committees, and all participants gave written informed consent in accordance with the Declaration of Helsinki.

### Antibodies

Alexa-647-conjugated anti-IL-21, biotinylated anti-ICOS, PE-anti-CD4, Pacific Blue-anti-CD4, peridinin chlorophyll protein complex (PerCP)/cyanine 5.5-anti-CD45RA, anti-IFNγ, and FITC-anti-CD45RA were purchased from eBiosciences. Alexa-647-anti-CXCR5, allophycocyanin-anti-CD38, FITC-anti-CD20, PE-anti-CD4, anti-CD27, PerCP-anti-CD3 mAb, and streptavidin-PerCP were purchased from Becton Dickinson. Allophycocyanin-anti-CD4 was purchased from Caltag, and FITC-anti-CCR7 was purchased from R&D Systems.

### CD4<sup>+</sup> T-cell isolation

CD4<sup>+</sup> T cells were isolated from healthy donors or immunodeficient patients with the use of Dynal beads.<sup>23</sup> Peripheral blood (PB) CD4<sup>+</sup> T cells were labeled with anti-CD4, anti-CD45RA, and anti-CCR7, and naive

**Table 2. Primers for qPCR**

Gene	Primers	UPL probe	Amplicon size, bp
<i>BCL6</i>	fwd: gagctctgttgattcctagaactgg rev: gccttgcttcacagtcctca	9	110
<i>TBX21</i>	fwd: tgtgtccaagttlaatcagca	9	77
<i>IL21</i>	rev: tgacaggaatgggaacatcc fwd: aggaaccacotccacaaa rev: gaatcacatgaaggcgatgt	7	68
<i>IFNG</i>	fwd: ggcattttgaagaattggaaag rev: ttggatgctctggctcatct	21	112
<i>GAPDH</i>	fwd: ctctgctcctcctgttcgac rev: acgaccaaatacctgtgactc	60	112

CD45RA<sup>+</sup>CCR7<sup>+</sup> CD4<sup>+</sup> T cells were isolated (> 98% purity) with the use of a FACSAria (BD Biosciences).

### Cell cultures

Naive PB CD4<sup>+</sup> T cells were labeled with CFSE (Molecular Probes) and cultured with T-cell activation and expansion beads (anti-CD2/CD3/CD28; Miltenyi Biotec) alone (nil culture) or under Th1 (IL-12 [20 ng/ml; R&D systems]), Th2 (IL-4 [100 U/ml]), or Th17 (IL-1β [20 ng/ml; Peprotech]), IL-6 (50 ng/mL; PeproTech), IL-21 (50 ng/mL; PeproTech), IL-23 (20 ng/mL; eBioscience), anti-IL-4 (5 μg/mL), and anti-IFNγ (5 μg/mL; eBioscience)<sup>23,29</sup> polarizing conditions, or with IL-6, IL-21, IL-23, or IL-27 (50 ng/mL; eBioscience) alone. After 4 or 5 days, expression of intracellular cytokines, transcription factors, and surface phenotype of cells determined.

### T- and B-cell coculture assays

Naive CD4<sup>+</sup> T cells were activated for 5 days (see previous section), treated with mitomycin C (100 μg/mL; Sigma-Aldrich) and then cocultured at a 1:1 ratio (50 × 10<sup>3</sup>/200 μL/well) with sort-purified allogeneic naive (CD20<sup>+</sup>CD27<sup>-</sup>CD38<sup>inter</sup>) tonsillar B cells.<sup>11,29</sup> After 7 days Ig secretion was determined by ELISA.<sup>29</sup>

### Cytokine and transcription factor expressions

Activated CD4<sup>+</sup> T cells were restimulated with phorbol 12-myristate 13-acetate (100 ng/mL) and ionomycin (750 ng/mL) for 6 hours, with Brefeldin A (10 μg/mL) added after 2 hours. Cells were then fixed with formaldehyde, and expression of cytokines was detected by intracellular staining.<sup>23,29</sup> RNA was extracted with the use of RNeasy kit (QIAGEN) and transcribed into cDNA with the use of random hexamers and Superscript III (Invitrogen). All quantitative PCR (qPCR) primers (Integrated DNA Technologies) were designed with Roche UPL Primer Design Program. Primer sequences, Roche UPL probes, and size of each amplicon are listed in Table 2. qPCR was performed with Roche LightCycler 480 Probe Master Mix and Roche Lightcycler 480 System with the following conditions: denaturation at 95°C for 10 minutes; amplification for 45 cycles at 95°C for 10 seconds, 65°C for 30 seconds, and 72°C for 5 seconds; and cooling at 40°C for 30 seconds. All reactions were standardized to *GAPDH*.

## Results


### Patients deficient for IL-12Rβ1 have altered differentiation of CD4<sup>+</sup> T cells in vivo

IL-12 can induce human naive CD4<sup>+</sup> T cells to differentiate into IL-21-expressing cells that resemble Tfh cells in vitro.<sup>11,22</sup> To investigate this function of IL-12 further, we examined patients with homozygous or compound heterozygous null mutations in *IL12RB1*.<sup>26</sup> We first determined the frequency of total CD4<sup>+</sup> T cells and CD4<sup>+</sup> T cells with a naive (CD45RA<sup>+</sup>CCR7<sup>+</sup>), memory (CD45RA<sup>-</sup>CCR7<sup>+</sup>), or Tfh (CXCR5<sup>+</sup>) phenotype in healthy

donors (age range, 16-64 years) and patients deficient for IL-12Rβ1 (Figure 1A-D,F). Patients deficient for IL-12Rβ1 had a normal frequency of CD4<sup>+</sup> T cells (Figure 1; Table 3). In contrast, they had a significant increase in the frequency of naive and a corresponding significant decrease in memory CD4<sup>+</sup> T cells (Figure 1A-E; Table 3). When the phenotype of CXCR5<sup>+</sup> T cells was analyzed, ~ 90% were found within the CD45RA<sup>-</sup> (ie, memory) subset (Table 3<sup>2,3,11</sup>). Therefore, we analyzed the frequency of both CXCR5<sup>+</sup>CD45RA<sup>-</sup> and CD45RA<sup>+</sup> T cells in healthy donors and in patients deficient for IL-12Rβ1. No significant difference was observed for the frequency of circulating CD4<sup>+</sup> CXCR5<sup>+</sup>CD45RA<sup>-</sup> or CD45RA<sup>+</sup> Tfh-like cells in healthy donors and patients deficient for IL-12Rβ1 (Figure 1A-B,F; Table 3).

### Naive CD4<sup>+</sup> T cells from patients deficient for IL-12Rβ1 are unable to differentiate into IL-21-expressing cells in response to IL-12

To assess the potential of CD4<sup>+</sup> T cells deficient for IL-12Rβ1 to differentiate into Tfh-like cells, we examined the ability of naive cells to express IL-21 in vitro. Naive CD4<sup>+</sup> T cells were cultured with T-cell activation and expansion beads alone (nil) or with IL-12 (Th1). After 5 days, cells were restimulated with phorbol 12-myristate 13-acetate/ionomycin, and the expression of IL-21 and IFNγ was then determined. Naive CD4<sup>+</sup> T cells from either healthy donors or patients deficient for IL-12Rβ1 expressed little IL-21 or IFNγ when cultured under neutral (nil) conditions (Figure 1G-J). However, when normal naive CD4<sup>+</sup> T cells were cultured under Th1-polarizing conditions (ie, with IL-12), IL-21- and IFNγ-expressing cells were readily detectable (Figure 1G,I,J). In contrast, IL-12 failed to induce IL-21 or IFNγ in naive CD4<sup>+</sup> T cells deficient for IL-12Rβ1 (Figure 1H-J). Next, we questioned whether naive CD4<sup>+</sup> T cells deficient for IL-12Rβ1 could differentiate into IL-21-expressing cells in response to other cytokines and signaling pathways. Accordingly, naive CD4<sup>+</sup> T cells from healthy donors and patients deficient for IL-12Rβ1 were subjected to Th2 (IL-4) and Th17 (IL-1β, IL-6, IL-21, IL-23) polarizing conditions or were cultured in the presence of IL-6, IL-21, IL-23, or IL-27. A small frequency of IL-21-expressing cells could be generated from both normal and IL-12Rβ1-deficient naive CD4<sup>+</sup> T cells activated with IL-21 or IL-27 (Figure 1I). Similarly, although IL-12 could not induce IFNγ in naive CD4<sup>+</sup> T cells deficient for IL-12Rβ1, the ability of IL-27 to induce IFNγ was unaffected by *IL12RB1* mutations (Figure 1J). Taken together these results indicate that, although IL-12-induced IL-21 expression is abrogated by *IL12RB1* mutations, other cytokines and their associated signaling pathways that induce IL-21 (eg, IL-21 and IL-27, albeit to a lesser extent than IL-12) are intact, which is consistent with normal Ab responses to infection and vaccinations in these patients.<sup>30,31</sup>



**Figure 1. Naive CD4<sup>+</sup> T cells deficient for IL-12Rβ1 fail to differentiate into IL-21-expressing cells in response to IL-12.** (A-F) The frequency of total CD4<sup>+</sup> T cells, and naive (CD45RA<sup>+</sup>CCR7<sup>+</sup>), and memory (CD45RA<sup>+</sup>CCR7<sup>-/+</sup>), and CXCR5<sup>+</sup>CD45RA<sup>-</sup> CD4<sup>+</sup> T cells, in PBMCs was determined for healthy donors and patients deficient for IL-12Rβ1. (A-B) Representative dot plots from 1 donor and 1 patient. (C-F) The frequency of (C) total, (D) naive (CD45RA<sup>+</sup>CCR7<sup>+</sup>), (E) memory (CD45RA<sup>+</sup>CCR7<sup>-/+</sup>), and (F) CXCR5<sup>+</sup>CD45RA<sup>-</sup> CD4<sup>+</sup> T cells from all healthy donors (total CD4<sup>+</sup> T cells, n = 54; naive CD4<sup>+</sup> T cells, n = 70; memory CD4<sup>+</sup> T cells, n = 70; CXCR5<sup>+</sup>CD45RA<sup>-</sup> CD4<sup>+</sup> T cells, n = 61) and patients deficient for IL-12Rβ1 examined (n = 6). (G-J) Naive CD4<sup>+</sup> T cells isolated from healthy donors (n = 5) and patients deficient for IL-12Rβ1 (n = 5) were cultured for 5 days under neutral (nil); polarizing Th1, Th2, or Th17 conditions; or in the presence of IL-6, IL-21, IL-23, or IL-27, and intracellular expression of IL-21 and IFN<sub>γ</sub> were then determined. (G-H) Representative dot plots of IL-21 and IFN<sub>γ</sub> expression by activated naive CD4<sup>+</sup> T cells from 1 donor and 1 patient deficient for IL-12Rβ1. (I-J) Percentage of activated normal and IL-12Rβ1-deficient naive CD4<sup>+</sup> T cells induced to express (I) IL-21 or (J) IFN<sub>γ</sub> in response to the indicated culture. The values represent the mean ± SEM.

**Analysis of cytokine responsiveness in STAT-deficient human CD4<sup>+</sup> T cells**

The cytokines that induce IL-21 in human naive CD4<sup>+</sup> T cells (IL-12, IL-6, IL-21, IL-23, IL-27)<sup>11,22</sup> function by activating

JAK/STAT signaling pathways. These cytokines phosphorylate STAT1 (IL-6, IL-12, IL-21, IL-23, IL-27), STAT3 (IL-6, IL-12, IL-21, IL-23, IL-27), STAT4 (IL-12, IL-23), and STAT5 (IL-12).<sup>20,21,24,32-35</sup> We confirmed these studies by showing that these

**Table 3. CD4<sup>+</sup> T-cell subsets in primary immunodeficiencies**

PID	CD4 <sup>+</sup> T cells	Naive CD4 <sup>+</sup> T cells	Memory CD4 <sup>+</sup> T cells	CXCR5 <sup>+</sup> CD45RA <sup>+</sup> CD4 <sup>+</sup> T cells	CXCR5 <sup>+</sup> CD45RA <sup>-</sup> CD4 <sup>+</sup> T cells
IL12RB1 (n = 6)	40 ± 4.4	71 ± 4.7	28 ± 4.7	1.6 ± 0.46	14 ± 2.8
STAT1 (n = 6)	40*	41 ± 10	56 ± 10	3.9 ± 0.68	11 ± 2.3
STAT3 (n = 14)	41 ± 3.1	65 ± 3.8	33 ± 3.7	1.5 ± 0.29 (n = 11)	8.7 ± 1.6 (n = 11)
TYK2 (n = 2)	41*	53 ± 24	43 ± 27	2.8 ± 1.2	15 ± 5.4
Controls	43 ± 1.4 (n = 54)	39 ± 1.7 (n = 70)	59 ± 1.7 (n = 70)	2.8 ± 0.24 (n = 61)	15 ± 1.1 (n = 61)

Values are mean ± SEM percentage.  
 PID indicates primary immunodeficiency.  
 \*Analysis was only performed on 1 patient.

IL-12–inducing cytokines predominantly activate STAT1, STAT3, and STAT4 in human naive CD4<sup>+</sup> T cells (data not shown), suggesting that these transcription factors are important in inducing T<sub>fh</sub> cells in humans. To investigate this further, we took advantage of additional primary immunodeficiencies that result from mutations in components of several cytokine-signaling pathways, namely *STAT1*, *TYK2*, and *STAT3*.

**STAT1 is dispensable for IL-12–induced expression of IL-21 in human CD4<sup>+</sup> T cells**

STAT1-deficient patients and healthy donors had comparable frequencies of naive and memory CD4<sup>+</sup> T cells (Figure 2A-D; Table 3). The proportions of CXCR5<sup>+</sup>CD45RA<sup>-</sup> or CD45RA<sup>+</sup> T<sub>fh</sub> cells in STAT1-deficient patients were also comparable with healthy donors (Figure 2A-B,E; Table 3). The ability of STAT1-deficient CD4<sup>+</sup> T cells to differentiate into IL-21<sup>+</sup> cells in response to Th1-polarizing conditions was then tested. Because of the limited numbers of cells available from these rare patients, total CD4<sup>+</sup> T cells were examined. When CD4<sup>+</sup> T cells from healthy donors or STAT1-deficient patients were activated under neutral conditions, IL-21 and IFN $\gamma$  production could be detected; however, the frequencies of cytokine-expressing cells was lower in STAT1-deficient patients (Figure 2F,H; IL-21: normal, 9.1% ± 6.2%; STAT1, 2.7% ± 1.8%; IFN $\gamma$ : normal, 11.3% ± 3.8%; STAT1, 1.6% ± 0.9%). Despite these differences in the nonpolarizing cultures, expression of IL-21 and IFN $\gamma$  in both normal and STAT1-deficient CD4<sup>+</sup> T cells increased after culture with IL-12 (Figure 2F,H; IL-21: normal, 30.5% ± 7.9%; STAT1, 13.2% ± 6.7%; IFN $\gamma$ : normal, 31.3% ± 7.9%; STAT1, 12.3% ± 2.5%). Although there appeared to be a reduced ability of IL-12 to enhance expression of IL-21 and IFN $\gamma$  in the absence of STAT1, compared with normal CD4<sup>+</sup> T cells (Figure 2F,H), when the effect of IL-12 was expressed as fold-change relative to nonpolarizing cultures, STAT1-deficient CD4<sup>+</sup> T cells responded comparably to normal cells, that is, ~ 4- to 6-fold increase in IL-21 (Figure 2G) and ~ 3- to 6-fold induction in IFN $\gamma$  expression (Figure 2I). Together these results indicate that IL-12–induced IL-21 and IFN $\gamma$  in CD4<sup>+</sup> T cells is independent of STAT1 signaling.


**Mutations in *STAT3* compromise the generation of CD4<sup>+</sup> memory and CXCR5<sup>+</sup> T<sub>fh</sub> cells**

To investigate further the signaling pathways involved in the differentiation of IL-21–expressing cells we used patients with autosomal-dominant hyper IgE syndrome resulting from heterozygous mutations in *STAT3*.<sup>36,37</sup> Patients heterozygous for these mutations display impaired, but not abolished, STAT3 function with ~ 25% residual signaling.<sup>36,37</sup> As detailed above, STAT3 is activated by many cytokines, including those that induce IL-21

expression in human CD4<sup>+</sup> T cells (ie, IL-6, IL-12, IL-21, IL-23, IL-27).<sup>20,21,24,32-35</sup> The frequency of total CD4<sup>+</sup> T cells was comparable between healthy donors and STAT3<sub>MUT</sub> patients (Figure 3C). Compared with healthy donors, STAT3<sub>MUT</sub> patients have a significant increase in the frequency of naive and a significant decrease in the frequency of memory CD4<sup>+</sup> T cells (Figure 3A-F; Table 3). Analysis of CXCR5<sup>+</sup> T cells within the CD45RA<sup>+</sup> and CD45RA<sup>-</sup> fractions revealed significant decreases in both of these compartments in STAT3<sub>MUT</sub> patients compared with healthy donors (Figure 3A-B,F; Table 3). Thus, mutations in *STAT3* cause a ~ 50% reduction in the frequency of circulating CXCR5<sup>+</sup>CD45RA<sup>-</sup> and CD45RA<sup>+</sup> T<sub>fh</sub> cells (Figure 3F; Table 3).

***STAT3* mutations partially impairs IL-12–induced expression of IL-21 in naive CD4<sup>+</sup> T cells**

The observations that (1) IL-12 is the main driver of human T<sub>fh</sub> cell differentiation *in vitro*,<sup>11,22</sup> (2) IL-12 is capable of activating STAT3,<sup>21,32-35</sup> and (3) STAT3<sub>MUT</sub> patients have a contracted population of circulating CD4<sup>+</sup> CXCR5<sup>+</sup>CD45RA<sup>-</sup> and CD45RA<sup>+</sup> T<sub>fh</sub>-like cells (Figure 3E) led us to investigate the consequences of *STAT3* mutations on the ability of IL-12 to induce IL-21 in human naive CD4<sup>+</sup> T cells. No differences were observed in the low frequencies of IL-21– and IFN $\gamma$ –expressing cells detected in cultures of naive CD4<sup>+</sup> T cells from healthy donors or STAT3<sub>MUT</sub> patients after stimulation under neutral conditions (Figure 4A-D). However, induction of IL-21 expression by IL-12 was significantly reduced in STAT3<sub>MUT</sub> naive CD4<sup>+</sup> T cells compared with normal naive CD4<sup>+</sup> T cells (Figure 4A-C; normal, 20.9% ± 4.5%; STAT3<sub>MUT</sub>, 5.2% ± 1.3%). In fact this defect was most pronounced when the frequency of IL-21<sup>+</sup>IFN $\gamma$ <sup>-</sup> cells were determined (Figure 4A-B). This analysis found a significant (*P* < .01) decrease in IL-21<sup>+</sup>IFN $\gamma$ <sup>-</sup> cells but not IL-21<sup>+</sup>IFN $\gamma$ <sup>+</sup> (*P* > .05) cells in STAT3<sub>MUT</sub> patients compared with healthy donors after Th1 polarization (IL-21<sup>+</sup>IFN $\gamma$ <sup>-</sup>: normal, 16.7% ± 3.2%; STAT3<sub>MUT</sub>, 2.3% ± 0.5%; IL-21<sup>+</sup>IFN $\gamma$ <sup>+</sup>: normal, 4.8% ± 1.5%; STAT3<sub>MUT</sub>, 3.3% ± 1%). In contrast to IL-21, expression of IFN $\gamma$  in CD4<sup>+</sup> T cells in response to IL-12 was unaffected by *STAT3* mutations; in fact it was higher than normal CD4<sup>+</sup> T cells (Figure 4D). This increase in IFN $\gamma$  production by STAT3<sub>MUT</sub> CD4<sup>+</sup> T cells, however, did not contribute to decreased IL-21 production because neutralizing IFN $\gamma$  in these cultures had no effect on IL-21 expression, and there was a positive correlation between IL-21 and IFN $\gamma$  expression in both normal and STAT3<sub>MUT</sub> naive CD4<sup>+</sup> T cells after Th1 polarization (data not shown). It was possible that induction of IL-21 by IL-12 resulted from not only a direct effect of IL-12 but also the effects of other cytokines induced by IL-12 that act in an autocrine manner to further promote IL-21 expression. To address this, we examined IL-21 and IFN $\gamma$  expression in normal and STAT3<sub>MUT</sub> CD4<sup>+</sup> T cells by qPCR after 24 and 48 hours of




**Figure 2. STAT1 is dispensable for IL-12-induced expression of IL-21 in human CD4<sup>+</sup> T cells.** (A-E) The frequency of naive (CD45RA<sup>+</sup>CCR7<sup>+</sup>), memory (CD45RA<sup>+</sup>CCR7<sup>-/+</sup>), and CXCR5<sup>+</sup>CD45RA<sup>-</sup> CD4<sup>+</sup> T cells in PBMCs was determined for healthy donors and STAT1-deficient patients. (A-B) Representative dot plots from 1 donor and 1 STAT1-deficient patient. (C-E) The frequency of (C) naive (CD45RA<sup>+</sup>CCR7<sup>+</sup>), (D) memory (CD45RA<sup>+</sup>CCR7<sup>-/+</sup>), and (E) CXCR5<sup>+</sup>CD45RA<sup>-</sup> CD4<sup>+</sup> T cells from all healthy donors (total CD4<sup>+</sup> T cells, n = 54; naive CD4<sup>+</sup> T cells, n = 70; memory CD4<sup>+</sup> T cells, n = 70; CXCR5<sup>+</sup>CD45RA<sup>-</sup> CD4<sup>+</sup> T cells, n = 61) and STAT1-deficient patients (n = 6) was examined. (F-I) Total CD4<sup>+</sup> T cells isolated from healthy donors and STAT1-deficient patients (n = 3) were cultured for 5 days under neutral (nil) or Th1-polarizing (ie, IL-12) conditions, and expression of intracellular IL-21 (F-G) and IFN $\gamma$  (H-I) was then determined. The graphs in panels F and H show the frequency of cytokine-positive cells; those in panels G and I depict cytokine expression after Th1 polarization as fold-increase relative to the nil culture in each experiment. The values represent the mean  $\pm$  SEM (n = 3).

stimulation with or without IL-12. Expression of *IL21* was substantially increased by IL-12 in normal CD4<sup>+</sup> T cells within 24 hours of stimulation, compared with cells cultured under neutral (nil) conditions, and similar levels were detected after 48 hours (supplemental Figure 1A-B, available on the *Blood* Web site; see the Supplemental Materials link at the top of the online article). Consistent with the flow cytometric analysis, expression of *IL21* in IL-12-activated STAT3<sub>MUT</sub> naive CD4<sup>+</sup> T cells was reduced compared with normal controls (supplemental Figure 1A-B). In contrast to *IL21*, *IFNG* was abundantly expressed by IL-12-treated STAT3<sub>MUT</sub> naive CD4<sup>+</sup> T cells; in fact, consistent with the intracellular staining data, *IFNG* expression by these cells exceeded that of normal naive CD4<sup>+</sup> T cells at the 48-hour time point

(supplemental Figure 1C-D). These data suggest that IL-12 acts directly to rapidly induce IL-21 expression in naive CD4<sup>+</sup> T cells.

IL-12 is capable of activating the JAK family protein tyrosine kinase TYK2,<sup>38</sup> which subsequently phosphorylates STATs, including STAT3.<sup>39</sup> Mutations in *TYK2* have been reported in 2 patients who developed susceptibility to various pathogens, including mycobacteria/Bacille Calmette-Guérin and herpes viruses.<sup>25,28</sup> One of the contributing factors to disease pathogenesis is believed to be the unresponsiveness of their T cells to IL-12 with respect to induction of IFN $\gamma$  expression.<sup>25</sup> To investigate this further, these 2 patients deficient for TYK2 were examined (supplemental Figure 2). CXCR5<sup>+</sup>CD45RA<sup>-</sup> Tfh-like cells were detected in both patients at similar frequencies as healthy donors (supplemental Figure 2A-B,E; Table 3). When IL-21 expression in total



**Figure 3. Mutations in *STAT3* compromise the generation of CD4<sup>+</sup> memory and CXCR5<sup>+</sup>CD45RA<sup>-</sup> Tfh cells.** (A-B) The frequency of naive (CD45RA<sup>+</sup>CCR7<sup>+</sup>), memory (CD45RA<sup>+</sup>CCR7<sup>-/-</sup>), and CXCR5<sup>+</sup>CD45RA<sup>-</sup> CD4<sup>+</sup> T cells in PBMCs was determined for healthy donors and STAT3<sub>MUT</sub> patients. (A-B) Representative dot plots from 1 donor and 1 patient. (C-F) The frequency of (C) total CD4<sup>+</sup> T cells, (D) naive (CD45RA<sup>+</sup>CCR7<sup>+</sup>), (E) memory (CD45RA<sup>+</sup>CCR7<sup>-/-</sup>), and (F) CXCR5<sup>+</sup>CD45RA<sup>-</sup> CD4<sup>+</sup> T cells from all healthy donors (total CD4<sup>+</sup> T cells, n = 54; naive CD4<sup>+</sup> T cells, n = 70; memory CD4<sup>+</sup> T cells, n = 70; CXCR5<sup>+</sup>CD45RA<sup>-</sup> CD4<sup>+</sup> T cells, n = 61) and STAT3<sub>MUT</sub> patients (n = 14) was examined.

CD4<sup>+</sup> T cells from 1 patient deficient for *TYK2* after culture with IL-12 was examined, the level of induction was ~2-fold less than that observed for normal CD4<sup>+</sup> T cells (supplemental Figure 2F-G). We extended these studies by examining naive CD4<sup>+</sup> T cells from the second patient deficient for *TYK2*. Compared with normal naive CD4<sup>+</sup> T cells, induction of IL-21 expression by IL-12 in *TYK2*-deficient CD4<sup>+</sup> T cells was severely reduced (supplemental Figure 2I). Induction of IFN $\gamma$  was also dramatically compromised by *TYK2* mutations (supplemental Figure 2H,J). Taken together, these data suggest that mutations in *TYK2* and *STAT3*, which are both activated downstream of the IL-12R,<sup>21,32-35,38,39</sup> cause a significant impairment in the ability of naive CD4<sup>+</sup> T cells to differentiate into IL-21-expressing cells in response to IL-12.

#### **STAT3 mutations impede division-linked differentiation of CD4<sup>+</sup> T cells into IL-21-expressing effector cells**


Because IL-12 can promote proliferation of human activated T cells,<sup>40</sup> and differentiation of CD4<sup>+</sup> T cells into cytokine-expressing cells is linked to cell division,<sup>29,41</sup> it was important to determine whether the reduction in expression of IL-21 in IL-12-stimulated STAT3<sub>MUT</sub> CD4<sup>+</sup> T cells resulted from reduced cell division or reflected an intrinsic defect in the differentiation program of these cells.

To do this, we examined proliferation by labeling naive CD4<sup>+</sup> T cells with CFSE and tracked their division after in vitro stimulation by monitoring CFSE dilution. There was no difference in cell division between normal or STAT3<sub>MUT</sub> naive CD4<sup>+</sup> T cells

activated under neutral conditions (Figure 4E). Similarly, IL-12 increased proliferation regardless of whether the naive CD4<sup>+</sup> T cells were derived from healthy donors or STAT3<sub>MUT</sub> patients (Figure 4E). When IL-21 expression was examined on a per division basis, we found that it increased in normal CD4<sup>+</sup> T cells after the first few divisions and then reached a maximum, being expressed in ~20%-30% of cells after 2-3 divisions (Figure 4F). Expression of IL-21 by STAT3<sub>MUT</sub> CD4<sup>+</sup> T cells also modestly increased with division; however, the frequency of IL-21<sup>+</sup> cells in each division never exceeded 10% and thus was dramatically reduced compared with normal CD4<sup>+</sup> T cells (Figure 4F). These data establish that the defect in IL-12-induced IL-21 induction in the absence of functional STAT3 was not because of a difference in proliferation, but rather because of an inability to efficiently acquire IL-21 during Tfh cell differentiation. Notably, when IFN $\gamma$  expression was also analyzed on a per division basis, the frequency of cytokine-positive cells continued to increase with each cell division (Figure 4G). Furthermore, the heightened frequency of IFN $\gamma$ <sup>+</sup> cells observed in STAT3<sub>MUT</sub> compared with normal CD4<sup>+</sup> T cells at the population level (Figure 4D and supplemental Figure 1) was also detected for cells that had undergone different divisions (Figure 4G).

#### **IL-12 can induce additional characteristics of Tfh cells in STAT3 mutant CD4<sup>+</sup> T cells**

IL-12 not only promotes IL-21 expression in human naive CD4<sup>+</sup> T cells but also induces additional features of Tfh cells such as




**Figure 4.** STAT3 mutations impair IL-12–induced expression of IL-21 in naive CD4<sup>+</sup> T cells. (A–D) Naive CD4<sup>+</sup> T cells isolated from healthy donors (n = 8) and STAT3<sub>MUT</sub> patients (n = 9) were cultured for 5 days under neutral conditions (nil); polarizing Th1, Th2, or Th17 conditions; or in the presence of IL-6, IL-21, IL-23, or IL-27, after which time expression of intracellular IL-21 and IFN $\gamma$  was determined. (A–B) Representative dot plots of cytokine expression by activated naive CD4<sup>+</sup> T cells from 1 donor and 1 patient. (C–D) Percentage of activated normal and STAT3<sub>MUT</sub> naive CD4<sup>+</sup> T cells induced to express (C) IL-21 or (D) IFN $\gamma$  in response to the indicated culture. The values represent the mean  $\pm$  SEM. (E–F) Naive CD4<sup>+</sup> T cells isolated from healthy donors and STAT3<sub>MUT</sub> patients were labeled with CFSE and cultured with anti-CD2/CD3/CD28 Abs in the absence (nil) or presence of Th1 polarizing conditions (+IL-12). After 5 days cells were harvested, and (E) proliferation and expression of (F) IL-21 and (G) IFN $\gamma$  in cells that had undergone different divisions were then determined. (F–G) The values represent the mean  $\pm$  SEM (n = 3).

sustained expression of CXCR5 and ICOS, and a modest induction of the Tfh lineage restricted transcription factor *BCL6*.<sup>4,11</sup> We

therefore wanted to explore whether the effects of IL-12 on these aspects of CD4<sup>+</sup> T-cell activation were also compromised by


**Figure 5. Induction of CXCR5, ICOS, and *BCL6* by IL-12 in CD4<sup>+</sup> T cells is independent of STAT3.** (A-D) Naive CD4<sup>+</sup> T cells isolated from healthy donors and STAT3<sub>MUT</sub> patients were cultured with anti-CD2/CD3/CD28 Abs in the absence (nil) or presence of Th1-polarizing conditions (+IL-12). After 4 days the cells were harvested, and surface expression of CXCR5 and ICOS was determined by flow cytometry and of *TBX21* and *BCL6* by qPCR. (A,C) representative histogram plots from 1 healthy donor and 1 STAT3<sub>MUT</sub> patient. Expression of (B) CXCR5 (n = 3), (D) ICOS (n = 3), (E) *TBX21* (n = 4), and (F) *BCL6* (n = 5) after Th1 polarization is presented as fold-increase compared with the nil culture in each experiment. (B,D-F) The graphs represent the mean ± SEM of the indicated number of experiments.



mutations in *STAT3*. Compared with naive CD4<sup>+</sup> T cells activated under neutral conditions, elevated expression of the Tfh cell markers CXCR5 and ICOS was observed when either normal or STAT3<sub>MUT</sub> cells were activated in the presence of IL-12 (Figure 5 A,C). In fact, compared with cells cultured under neutral conditions, IL-12 up-regulated CXCR5 and ICOS expressions by 2- to 3-fold on both normal and STAT3<sub>MUT</sub> naive CD4<sup>+</sup> T cells (Figure 5B,D). IL-12 also up-regulated *TBX21* (encoding T-bet) and *BCL6*, the transcription factors required to generate Th1 and Tfh cells, respectively, to a comparable extent in normal and STAT3<sub>MUT</sub> naive CD4<sup>+</sup> T cells (Figure 5E,F). Thus, IL-12-mediated induction of CXCR5, ICOS, and *BCL6* in Tfh-like cells either only require the residual levels of functional STAT3 that are available in STAT3<sub>MUT</sub> CD4<sup>+</sup> T cells or are STAT3-independent resulting from IL-12-induced activation of STAT4.<sup>20,21,34,38</sup> This

latter scenario would underlie the normal induction of *TBX21* and IFN $\gamma$  in STAT3<sub>MUT</sub> Th1 cells.

Consistent with our previous findings,<sup>11</sup> most of the other culture conditions used in this study (ie, Th2- and Th17-polarizing conditions; exogenous IL-6, IL-21, IL-23) had no effect on expression of CXCR5 and ICOS on normal CD4<sup>+</sup> T cells above that observed for the nonpolarizing culture (supplemental Figure 3A-B). However, IL-27 did modestly enhance ICOS expression (supplemental Figure 3B) and induce *TBX21* in naive CD4<sup>+</sup> T cells (supplemental Figure 3C), and this was independent of STAT3. Interestingly, Th17 polarizing culture conditions induced the greatest levels of *BCL6* in naive CD4<sup>+</sup> T cells, and this was substantially reduced in STAT3<sub>MUT</sub> CD4<sup>+</sup> T cells (supplemental Figure 3D), reflecting the contribution of STAT3 to the combined signaling of IL-6, IL-21, and IL-23 through their respective receptors.



**Figure 6. STAT3-deficient cells show impaired Tfh cell function in vitro.** Naive CD4<sup>+</sup> T cells isolated from healthy donors (HD) and STAT3<sub>MUT</sub> patients (Pt) were cultured under neutral (nil) or Th1 polarizing conditions. After 5 days, the cells were harvested and treated with mitomycin C before being cocultured with allogeneic naive B cells, in the absence or presence of exogenous IL-21, for an additional 7 days. After this time secretion of IgM, IgG, and IgA was determined. (A-B) The data were derived from experiments that used naive CD4<sup>+</sup> T cells isolated from different STAT3<sub>MUT</sub> patients; (C) the data show the effect of exogenous IL-21 on the ability of STAT3<sub>MUT</sub> CD4<sup>+</sup> T cells to provide B-cell help. Each graph represents the mean ± SEM of triplicate cultures; similar results were obtained in 5 (A-B) and 2 (C) experiments.

#### Defective IL-21 production by STAT3<sub>MUT</sub> CD4<sup>+</sup> T cells results in impaired Tfh cell function in vitro

We next questioned whether a reduction in IL-21 expression in STAT3<sub>MUT</sub> CD4<sup>+</sup> T cells would result in a detectable functional defect, such as a compromised ability of these cells to provide help to B cells. To investigate this, we established an in vitro B-cell helper assay in which naive CD4<sup>+</sup> T cells were isolated from healthy donors and STAT3<sub>MUT</sub> patients and activated under neutral or Th1-polarizing conditions. After 5 days, the CD4<sup>+</sup> T cells were harvested and cocultured with naive B cells for an additional 7 days, after which time Ig secretion was quantified. Normal naive CD4<sup>+</sup> T cells activated under Th1 conditions provided significantly more help to support Ig production by cocultured B cells than when these T cells were cultured under neutral conditions (Figure 6A-C). Although priming under Th1 conditions also increased the helper function of STAT3<sub>MUT</sub> CD4<sup>+</sup> T cells relative to those cultured under neutral conditions, it was significantly less than that of normal CD4<sup>+</sup> T cells (Figure 6A-C). This reduction in B-cell help by IL-12-stimulated STAT3<sub>MUT</sub> CD4<sup>+</sup> T cells approximated their reduction in expression of IL-21 under these culture conditions (ie, ~50%-70%; compare Figures 4C and 6A-C), thereby suggesting that the impaired ability of STAT3<sub>MUT</sub> CD4<sup>+</sup> T cells to adequately promote B-cell differentiation resulted from insufficient production of IL-21. Indeed, the reduced ability of IL-12-primed STAT3<sub>MUT</sub> CD4<sup>+</sup> T cells to provide help to B cells could be overcome when IL-21 was added to the cocultures (Figure 6C). Thus, functional STAT3 deficiency compromises the ability of IL-12 to induce IL-21, which is subsequently detrimental to the capacity of these CD4<sup>+</sup> T cells to mediate the differentiation of B cells into Ig-secreting cells.

#### STAT3 mutations abolish IL-21 expression in naive CD4<sup>+</sup> T cells induced by IL-6, IL-21, IL-23, and IL-27

As previously shown, other cytokines (IL-6, IL-21, IL-23, IL-27) can also give rise to IL-21-expressing cells, albeit to a much lesser extent than IL-12.<sup>11,17,22</sup> When STAT3<sub>MUT</sub> naive CD4<sup>+</sup> T cells were exposed to these cytokines, they were unable to up-regulate IL-21

expression (Figure 4C). Thus, although mutations in *STAT3* substantially reduced the ability of IL-12 to induce IL-21 expression in CD4<sup>+</sup> T cells, the ability of IL-6, IL-21, IL-23, and IL-27 to do this was completely dependent on STAT3. Consistent with this, STAT3<sub>MUT</sub> naive CD4<sup>+</sup> T cells preactivated with IL-6, IL-21, or IL-23 were unable to support Ab production by cocultured B cells (supplemental Figure 3E-F).

## Discussion

Lymphocyte differentiation is the outcome of the integration of signals from numerous external stimuli and the activation of specific transcription factors that regulate gene expression and ultimately cellular function. The differentiation of naive CD4<sup>+</sup> T cells into Th1, Th2, Th17, and T-regulatory cells has been well-characterized for the roles of specific cytokines and transcription factors. The emergence of Tfh cells as the predominant subset of CD4<sup>+</sup> T cells that mediate TD humoral immunity has been accompanied by the elucidation of the requirements for their generation and maintenance. Thus, engaging the TCR, ICOS, and the SLAM/SAP pathways by ligands present on APCs, together with signals mediated by STAT3 downstream of receptors for the cytokines IL-6, IL-21, and IL-27, coordinately induce expression of the transcription factors BCL6, IRF4, and c-MAF, which converge to yield Tfh cells.<sup>8,12</sup> Despite these generalized findings, much controversy remains over the relative contribution of these individual components to Tfh cell formation; this is most apparent from subsequent studies that have challenged the role of IL-6 and IL-21 in this process.<sup>8,12,18,19</sup> Furthermore, the molecular requirements for the generation of human Tfh cells remain incompletely defined.

We and others previously showed that IL-12 plays an important role in the differentiation of human Tfh cells, as evidenced by its ability to induce expression of IL-21 and to maintain expression of ICOS and CXCR5 on naive CD4<sup>+</sup> T cells.<sup>11,22</sup> Similar to studies in mice,<sup>7,14,17</sup> IL-6, IL-21, and IL-27 also induce IL-21 expression in human naive CD4<sup>+</sup> T cells, albeit to a much lesser extent than

IL-12.<sup>11,17,22</sup> We have now substantially extended these findings by investigating the *in vivo* and *in vitro* development of Tfh cells in patients with loss-of-function mutations in *IL-12RB1*, *STAT1*, *TYK2*, and *STAT3*; that is genes that compromise cytokine-mediated intracellular signaling pathways probably involved in regulating human Tfh cell formation.

The specific ability of IL-12 to induce IL-21 expression in human naive CD4<sup>+</sup> T cells was confirmed by showing that in the absence of a functional receptor (ie, in patients deficient for IL-12Rβ1) IL-12 was unable to give rise to IL-21-expressing cells (Figure 1I). Interestingly, IL-12-mediated IL-21 expression partially depended on intact STAT3 signaling, because heterozygous mutations in *STAT3* (which render most STAT3 dimers nonfunctional) reduced IL-21 expression by 50%-75%. Induction of IL-21 expression in CD4<sup>+</sup> T cells by IL-12 was also reduced in the absence of TYK2 but was unaffected by STAT1 deficiency. Further evidence that the generation of human Tfh cells is STAT1 independent was the finding that the frequency of circulating CXCR5<sup>+</sup>CD45RA<sup>-</sup> T cells was unaffected by gain-of-function mutations in *STAT1* (22% ± 6.6%; n = 3). Although IL-12 is well-characterized for its ability to operate via STAT4-dependent pathways,<sup>20</sup> our finding of a requirement for STAT3 in IL-12 function is consistent with numerous studies that have documented STAT3 activation in human and murine T cells exposed to IL-12.<sup>21,33,34,38,42</sup> TYK2 is similarly phosphorylated in IL-12-treated T cells.<sup>20,38,39</sup> Despite the defect in IL-21 production, IL-12 could still induce STAT3<sub>MUT</sub> naive CD4<sup>+</sup> T cells to acquire other characteristics of Tfh cells such as increased expression of ICOS, CXCR5, and *BCL6* (Figure 5A-D). The intact induction of these phenotypic and molecular changes in Tfh-like cells, as well as residual expression of IL-21, in IL-12-treated CD4<sup>+</sup> T cells derived from STAT3<sub>MUT</sub> patients, are probably induced in a STAT4-dependent manner. Thus, IL-12 induces IL-21 expression predominantly through a TYK2/STAT3-dependent mechanism, with a minor contribution via STAT4 signaling. This is supported by the ability of both STAT3 and STAT4 to bind the promoters of the *IL21* and *BCL6* genes<sup>43,44</sup> and also by the recent finding that IL-12 induces IL-21 in murine CD4<sup>+</sup> T cells via STAT3- and STAT4-dependent pathways.<sup>42</sup> Importantly, the reduction in IL-12-induced expression of IL-21 in STAT3<sub>MUT</sub> CD4<sup>+</sup> T cells translated to a functional defect in TD B-cell differentiation *in vitro* (Figure 6). Interestingly, although IL-12 could still induce normal levels of ICOS on STAT3<sub>MUT</sub> CD4<sup>+</sup> T cells, this could not compensate for the deficiency in IL-21 production by these T cells, which is the primary source of help for B-cell differentiation. These findings are consistent with a model in which ICOS has a dual role in Tfh cells, first, in their generation from naive precursors, and, second, in enhancing IL-21 expression.<sup>12,14,45,46</sup>

While the ability of IL-12 to induce IL-21 in naive CD4<sup>+</sup> T cells was predominantly STAT3-dependent, induction of IL-21 by IL-6, IL-21, and IL-27; and the ability of CD4<sup>+</sup> T cells primed with these cytokines to help B cells, were completely abrogated by mutations in *STAT3*. Thus, the ability of all cytokines currently identified to induce IL-21 in human CD4<sup>+</sup> T cells, and subsequent B cell-helper function would be dramatically affected by *STAT3* mutations, that is, either strongly reduced or completely abolished. The importance of intact STAT3 signaling in generating human Tfh cells is reinforced by the significant reduction in the frequencies of circulating CD4<sup>+</sup> CXCR5<sup>+</sup> T cells in STAT3<sub>MUT</sub> patients. By contrast, the frequency of these CXCR5<sup>+</sup> Tfh-like cells was normal in patients deficient for IL-12Rβ1. This suggests that, although IL-12 induces the greatest frequency of IL-21-expressing CD4<sup>+</sup> T cells, there is sufficient redundancy among cytokine signaling pathways involved in generating Tfh cells to overcome the inability of CD4<sup>+</sup> T cells to give rise to Tfh cells in the absence of the IL-12 signaling. In other words, IL-6, IL-21, and IL-27 signaling

through STAT3 will still give rise to Tfh cells from *IL12RB1*-mutant CD4<sup>+</sup> T cells. This is supported by the observation that humoral immune responses are intact in patients deficient for IL-12Rβ1.<sup>26,30,31</sup> Given the critical role of Tfh cells in humoral immune responses, it makes teleologic sense that this level of redundancy evolved to protect against the detrimental effects of Tfh cell deficiency. In contrast, use of STAT3 by several cytokines in the generation of human Tfh cells provides an explanation for why STAT3<sub>MUT</sub> patients exhibit defects in humoral immune responses (including reductions in circulating CD4<sup>+</sup> CXCR5<sup>+</sup>CD45RA<sup>-</sup> and CD45RA<sup>+</sup> Tfh-like cells, memory B cells and an inability to mount protective Ab responses after vaccination or natural infection<sup>24,47,48</sup>) that cannot be compensated entirely by IL-12-dependent STAT4 signaling. These clinical, cellular, and serologic features of STAT3 deficiency are reminiscent of patients with mutations in *ICOS* and *CD40LG*,<sup>49,50</sup> which largely result from an absence of B-cell help by Tfh cells.<sup>49,50</sup> Thus, although an intrinsic defect resulting from the inability of B cells to respond to cytokines such as IL-6, IL-10, and IL-21 would contribute to the functional Ab deficiency in STAT3<sub>MUT</sub> patients,<sup>24</sup> this defect would be compounded further by the compromised generation and function of Tfh cells.

Overall, our findings have shed substantial light on the molecular requirements for generating human Tfh cells and have identified a signaling pathway that could be targeted to enhance Tfh cell generation in immunodeficient conditions. The corollary is that because dysregulated activation and/or generation of Tfh cells has been associated with autoimmunity in humans and mice, inhibiting this pathway may represent a novel approach to treating autoAb-mediated conditions.

## Acknowledgments

The authors thank the Garvan Flow Cytometry facility for cell sorting, Dr Rene de Waal Malefyt (DNAX) for providing reagents (IL-4, anti-IL-4 mAb), and the patients and their families for participating in this project.

This work was supported by project and program grants from the National Health and Medical Research Council (NHMRC) of Australia (C.S.M., E.K.D., M.B., D.A.F., M.C.C., and S.G.T.) and Rockefeller University Center for 541 Clinical and Translational science (SUL1RR024143; J.-L.C.). C.S.M. is a recipient of a Career Development Fellowship and S.G.T. is a recipient of a Senior Research Fellowship from the NHMRC of Australia.

## Authorship

Contribution: C.S.M. designed the research, performed experiments, analyzed and interpreted results, and wrote the manuscript; D.T.A., A.C., and E.K.D. performed experiments; J.B., S.B.-D., P.D.A., A.Y.K., D.A., D.E., K.M., S.S.K., Y.M., S.N., M.A.F., S.C., J.M.S., J.P., M.W., P.G., M.C.C., D.A.F., and J.-L.C. provided patient samples and clinical details; M.C.C. also genotyped STAT3-mutant patients; M.B. provided intellectual input; and S.G.T. designed the research, interpreted results, and wrote the manuscript. All authors commented on the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Cindy S. Ma, Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, 2010 NSW, Australia; e-mail: c.ma@garvan.org.au; or Stuart G. Tangye, Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, 2010 NSW, Australia; e-mail: s.tangye@garvan.org.au.

## References

- Tangye SG, Deenick EK, Palendira U, Ma CS. T cell-B cell interactions in primary immunodeficiencies. *Ann N Y Acad Sci*. 2012;1250(1):1-13.
- Breitfeld D, Ohl L, Kremmer E, et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. *J Exp Med*. 2000;192(11):1545-1552.
- Schaerli P, Willmann K, Lang AB, Lipp M, Loetscher P, Moser B. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. *J Exp Med*. 2000;192(11):1553-1562.
- Chtanova T, Tangye SG, Newton R, et al. T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells. *J Immunol*. 2004;173(1):68-78.
- Yu D, Rao S, Tsai LM, et al. The transcriptional repressor Bcl-6 directs T follicular helper cell lineage commitment. *Immunity*. 2009;31(3):457-468.
- Johnston RJ, Poholek AC, Ditoro D, et al. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. *Science*. 2009;325(5943):1006-1010.
- Nurieva RI, Chung Y, Martinez GJ, et al. Bcl6 mediates the development of T follicular helper cells. *Science*. 2009;325(5943):1001-1005.
- Deenick EK, Ma CS. The regulation and role of T follicular helper cells in immunity. *Immunology*. 2011;134(4):361-367.
- Ma CS, Deenick EK. The role of SAP and SLAM family molecules in the humoral immune response. *Ann N Y Acad Sci*. 2011;1217:32-44.
- Rasheed A-U, Rahn H-P, Sallusto F, Lipp M, Müller G. Follicular B helper T cell activity is confined to CXCR5(hi)ICOS(hi) CD4 T cells and is independent of CD57 expression. *Eur J Immunol*. 2006;36(7):1892-1903.
- Ma CS, Suryani S, Avery DT, et al. Early commitment of naive human CD4(+) T cells to the T follicular helper (T<sub>FH</sub>) cell lineage is induced by IL-12. *Immunol Cell Biol*. 2009;87(8):590-600.
- Deenick EK, Ma CS, Brink R, Tangye SG. Regulation of T follicular helper cell formation and function by antigen presenting cells. *Curr Opin Immunol*. 2011;23(1):111-118.
- Vogelzang A, McGuire HM, Yu D, Sprent J, Mackay CR, King C. A fundamental role for interleukin-21 in the generation of T follicular helper cells. *Immunity*. 2008;29(1):127-137.
- Nurieva RI, Chung Y, Hwang D, et al. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. *Immunity*. 2008;29(1):138-149.
- Dienz O, Eaton SM, Bond JP, et al. The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells. *J Exp Med*. 2009;206(1):69-78.
- Eddahri F, Denanglaire S, Bureau F, et al. Interleukin-6/STAT3 signaling regulates the ability of naive T cells to acquire B-cell help capacities. *Blood*. 2009;113(11):2426-2433.
- Batten M, Ramamoorthi N, Kijavini NM, et al. IL-27 supports germinal center function by enhancing IL-21 production and the function of T follicular helper cells. *J Exp Med*. 2010;207(13):2895-2906.
- Poholek AC, Hansen K, Hernandez SG, et al. In vivo regulation of Bcl6 and T follicular helper cell development. *J Immunol*. 2010;185(1):313-326.
- Eto D, Lao C, Ditoro D, et al. IL-21 and IL-6 are critical for different aspects of B cell immunity and redundantly induce optimal follicular helper CD4 T cell (T<sub>FH</sub>) differentiation. *PLoS One*. 2011;6(3):e17739.
- Leonard WJ. Cytokines and immunodeficiency diseases. *Nat Rev Immunol*. 2001;1(3):200-208.
- Hibbert L, Pflanz S, De Waal Malefyt R, Kastelein RA. IL-27 and IFN-alpha signal via Stat1 and Stat3 and induce T-Bet and IL-12Rbeta2 in naive T cells. *J Interferon Cytokine Res*. 2003;23(9):513-522.
- Schmitt N, Morita R, Bourdery L, et al. Human dendritic cells induce the differentiation of interleukin-21-producing T follicular helper-like cells through interleukin-12. *Immunity*. 2009;31(1):158-169.
- Ma CS, Chew GYJ, Simpson N, et al. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. *J Exp Med*. 2008;205(7):1551-1557.
- Avery DT, Deenick EK, Ma CS, et al. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. *J Exp Med*. 2010;207(1):155-171.
- Minegishi Y, Saito M, Morio T, et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. *Immunity*. 2006;25(5):745-755.
- de Beaucoudrey L, Samarina A, Bustamante J, et al. Revisiting human IL-12Rbeta1 deficiency: a survey of 141 patients from 30 countries. *Medicine (Baltimore)*. 2010;89(6):381-402.
- Woellner C, Gertz EM, Schaffer AA, et al. Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome. *J Allergy Clin Immunol*. 2010;125(2):424-432.e428.
- Kilic SS, Hacimustafaoglu M, Boisson-Dupuis S, et al. A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome [published online ahead of print March 6, 2012]. *J Pediatr*. doi: 10.1016/j.peds.2012.01.056.
- Ma CS, Hare NJ, Nichols KE, et al. Impaired humoral immunity in X-linked lymphoproliferative disease is associated with defective IL-10 production by CD4+ T cells. *J Clin Invest*. 2005;115(4):1049-1059.
- Altare F, Durandy A, Lammas D, et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. *Science*. 1998;280(5368):1432-1435.
- de Jong R, Altare F, Haagen IA, et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. *Science*. 1998;280(5368):1435-1438.
- Parham C, Chirica M, Timans J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. *J Immunol*. 2002;168(11):5699-5708.
- Gollob JA, Veenstra KG, Jyonouchi H, et al. Impairment of STAT activation by IL-12 in a patient with atypical mycobacterial and staphylococcal infections. *J Immunol*. 2000;165(7):4120-4126.
- Jacobson NG, Szabo SJ, Weber-Nordt RM, et al. Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4. *J Exp Med*. 1995;181(5):1755-1762.
- Bacon CM, Petricoin EF III, Ortaldo JR, et al. Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes. *Proc Natl Acad Sci U S A*. 1995;92(16):7307-7311.
- Minegishi Y, Saito M, Tsuchiya S, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. *Nature*. 2007;448(7157):1058-1062.
- Holland SM, DeLeo FR, Elloumi HZ, et al. STAT3 mutations in the hyper-IgE syndrome. *N Engl J Med*. 2007;357(16):1608-1619.
- Bacon CM, McVicar DW, Ortaldo JR, Rees RC, O'Shea JJ, Johnston JA. Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of Janus family tyrosine kinases by IL-2 and IL-12. *J Exp Med*. 1995;181(1):399-404.
- Watford WT, O'Shea JJ. Human tyk2 kinase deficiency: another primary immunodeficiency syndrome. *Immunity*. 2006;25(5):695-697.
- Kubin M, Kamoun M, Trinchieri G. Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. *J Exp Med*. 1994;180(1):211-222.
- Gett AV, Hodgkin PD. Cell division regulates the T cell cytokine repertoire, revealing a mechanism underlying immune class regulation. *Proc Natl Acad Sci U S A*. 1998;95(16):9488-9493.
- Nakayamada S, Kanno Y, Takahashi H, et al. Early Th1 cell differentiation is marked by a T<sub>FH</sub> cell-like transition. *Immunity*. 2011;35(6):919-931.
- Wei L, Laurence A, Elias KM, O'Shea JJ. IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. *J Biol Chem*. 2007;282(48):34605-34610.
- Wei L, Vahedi G, Sun HW, et al. Discrete roles of STAT4 and STAT6 transcription factors in tuning epigenetic modifications and transcription during T helper cell differentiation. *Immunity*. 2010;32(6):840-851.
- Akiba H, Takeda K, Kojima Y, et al. The role of ICOS in the CXCR5+ follicular B helper T cell maintenance in vivo. *J Immunol*. 2005;175(4):2340-2348.
- Choi YS, Kageyama R, Eto D, et al. ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6. *Immunity*. 2011;34(6):932-946.
- Speckmann C, Enders A, Woellner C, et al. Reduced memory B cells in patients with hyper IgE syndrome. *Clin Immunol*. 2008;129(3):448-454.
- Sheerin KA, Buckley RH. Antibody responses to protein, polysaccharide, and phi X174 antigens in the hyperimmunoglobulinemia E (hyper-IgE) syndrome. *J Allergy Clin Immunol*. 1991;87(4):803-811.
- Yong PF, Salzer U, Grimbacher B. The role of costimulation in antibody deficiencies: ICOS and common variable immunodeficiency. *Immunol Rev*. 2009;229(1):101-113.
- Al-Herz W, Bousfiha A, Casanova J-L, et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency. *Front Immunol*. 2011;2:1-26.